Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares (KNSA) Covered Calls
You can sell covered calls on Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for KNSA (prices last updated Mon 4:16 PM ET):
| Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares (KNSA) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 37.03 | -0.86 | 36.65 | 37.49 | 337K | 947 | 1.6 |
| Covered Calls For Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares (KNSA) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Oct 17 | 35 | 1.10 | 36.39 | -3.8% | -277.4% | |
| Nov 21 | 35 | 2.40 | 35.09 | -0.3% | -2.7% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Extended Business Description
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase III clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody that is in Phase II clinical trials for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and in Phase 1a clinical trial for the treatment of atopic dermatitis. The company's preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40/CD40L interaction, a central control node of T-cell-dependent, and B-cell-mediated humoral adaptive immunity. The company has a clinical collaboration with Kite Pharma, Inc. to evaluate investigational combination of Yescarta and Mavrilimumab in patients with relapsed or refractory Large B-Cell lymphoma. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.
| Top 10 Open Interest For Oct 17 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | TSLA covered calls | 1. | ARCT covered calls | |
| 2. | IBIT covered calls | 7. | INTC covered calls | 2. | NVTS covered calls | |
| 3. | GLD covered calls | 8. | QQQ covered calls | 3. | HIVE covered calls | |
| 4. | SPY covered calls | 9. | IWM covered calls | 4. | AAOI covered calls | |
| 5. | SLV covered calls | 10. | AMZN covered calls | 5. | BTBT covered calls | |
Want more examples? KNOP Covered Calls | KNSL Covered Calls
